Illumina (NASDAQ:ILMN) SVP Christensen Jakob Wedel Sells 1,033 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Price Performance

ILMN stock opened at $213.24 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The firm has a market cap of $32.20 billion, a price-to-earnings ratio of 39.78, a PEG ratio of 2.89 and a beta of 1.45. The company’s fifty day simple moving average is $186.84 and its 200 day simple moving average is $151.97. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $220.32.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Illumina in the second quarter worth about $3,374,423,000. Plato Investment Management Ltd purchased a new stake in shares of Illumina during the 2nd quarter worth approximately $948,000. Impact Partnership Wealth LLC raised its holdings in shares of Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after purchasing an additional 7,780 shares during the period. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina in the 2nd quarter worth approximately $129,792,000. Finally, Insight Wealth Strategies LLC purchased a new position in Illumina in the second quarter valued at approximately $6,062,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Guggenheim raised their price objective on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Piper Sandler reiterated an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Citigroup boosted their target price on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.